Clinical Trials

LymphoidMyeloidOther hematologic neoplasm

86 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

69 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT06030089 2025-12-16

VENETACIBLE

Phase NA Completed

20 enrolled

Leukemia, Myeloid, Acute

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

445 enrolled 22 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04266795 2025-10-21

PEVENAZA

164 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04666649 2025-10-07

Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

27 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

211 enrolled 30 charts 3 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT05471700 2025-09-23

Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients

Phase NA Completed

40 enrolled

Leukemia, Myeloid, Acute

NCT04512105 2025-09-11

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

6 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT05662956 2025-07-15

A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

114 enrolled

Leukemia, Myeloid, Acute

NCT04589728 2025-07-08

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Completed

202 enrolled

Leukemia, Myeloid, Acute

NCT02397720 2025-06-08

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

150 enrolled 17 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05941585 2025-06-03

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Phase NA Completed

60 enrolled

Leukemia, Myeloid, Acute

NCT06993883 2025-05-29

AML

Completed

43 enrolled

Leukemia, Myeloid, Acute

NCT03063944 2025-05-15

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

37 enrolled

Leukemia, Myeloid, Acute

NCT04070768 2025-05-04

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

18 enrolled 15 charts

Recurrence, Leukemia, Myeloid, Acute

NCT04487106 2025-04-22

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

21 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04277442 2025-03-25

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

1 enrolled 8 charts

Leukemia, Myeloid, Acute

NCT02950051 2024-12-30

GAIA

926 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03787264 2024-12-30

CLL2-BAAG

46 enrolled

Leukemia, B-Cell

NCT02910583 2024-12-20

Captivate

323 enrolled 33 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03955783 2024-10-26

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

78 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT04017546 2024-09-19

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

14 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04267081 2024-09-04

VenEx

104 enrolled

Leukemia, Myeloid, Acute

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

120 enrolled 14 charts

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05433532 2024-04-25

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

LymphoidMyeloidOther hematologic neoplasm

20 enrolled

Philadelphia Chromosome, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04887857 2024-02-12

OMNIVERSE

6 enrolled

Leukemia, Myeloid, Acute

NCT03672695 2024-02-05

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

37 enrolled

Leukemia, Myeloid, Acute

NCT03739554 2024-01-25

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

5 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03455517 2023-11-24

VeRitAs

77 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02005471 2023-10-17

MURANO

389 enrolled 35 charts 4 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04075747 2023-10-16

V-FAST

57 enrolled

Leukemia, Myeloid, Acute

NCT03390296 2023-09-05

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

50 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT03873857 2023-09-01

FORTE

Completed

71 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01682616 2023-06-06

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

49 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04146038 2023-05-24

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

5 enrolled 9 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03236857 2023-05-22

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

CNSLymphoidOther hematologic neoplasm

143 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Neuroblastoma, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02756611 2023-04-10

VENICE I

258 enrolled 27 charts

Chromosome 17 deletion, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03941964 2023-03-20

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

60 enrolled 12 charts

Neoplasms, Leukemia, Myeloid, Acute

NCT02980731 2023-02-22

VENICE II

210 enrolled 36 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03194932 2023-02-14

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

62 enrolled